Pipelines, Not the Bottom Line, Define 2012 For Investors
Executive Summary
More than two dozen biotechs offer 2x returns in 2012, as investors pin their hopes on some hematology oncology and CNS plays. Investors think the party may continue into next year, but perhaps not so giddily.